Trial Profile
A phase 2 clinical trial of a replication-competent, recombinant herpes simplex virus type 1 in patients with glioblastoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 30 Aug 2022
Price :
$35
*
At a glance
- Drugs Teserpaturev (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 01 Aug 2022 Results published in the Nature Medicine
- 21 Jul 2022 Interim analysis results (n=13) published in the Nature Medicine.
- 11 Jun 2021 According to a Daiichi Sankyo Company media release, Results of the study will be submitted for publication by Dr. Todo